Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.67 |
| ▸ | EGLN3 | Q9H6Z9 | 7/20 | 0.62 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960754 | 0.87 | EGLN1 (0.71) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL1960755 | 0.84 | EGLN1 (0.64) | EGLN1EGLN3EGLN2 | |
| SCHEMBL8244419 | 0.80 | EGLN1 (1.00) | EGLN1EGLN3EGLN2KDM4ELMNA | |
| SCHEMBL8244773 | 0.79 | EGLN1 (0.76) | EGLN1EGLN3EGLN2KDM4ELMNA | |
| SCHEMBL3777755 | 0.78 | EGLN1 (0.61) | EGLN1EGLN3EGLN2 | |
| SCHEMBL8248294 | 0.77 | EGLN1 (0.77) | EGLN1EGLN3EGLN2KDM4E | |
| SCHEMBL1586113 | 0.77 | EGLN1 (0.49) | EGLN1EGLN3 | |
| SCHEMBL1640610 | 0.77 | EGLN3 (1.00) | EGLN1EGLN3EGLN2KDM4EL3MBTL1 | |
| SCHEMBL1640566 | 0.77 | EGLN3 (0.79) | EGLN1EGLN3EGLN2 | |
| SCHEMBL8244770 | 0.76 | EGLN1 (0.79) | EGLN1EGLN3EGLN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2011-06-16 | — | — | US | claimed |
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010025087-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144167-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 6/4885EGLN3 3/4885EGLN2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.